Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy.

This drug works by combining the antibody trastuzumab with a drug called emtansine. Trastuzumab works by binding to HER2 proteins that are found on the cells of HER2-positive breast cancer.

A team of scientists is investigating a new type of antibody, which stimulates the immune system to target cancer cells and slows tumour growth in ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Zymeworks (NasdaqGS:ZYME) with a Outperform ...

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and ...

Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening ...